Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Dec;83(12):1762–1768. doi: 10.1054/bjoc.2000.1500

Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors

C Ferlini 1, M Distefano 1, F Pignatelli 1, S Lin 2, A Riva 3, E Bombardelli 3, S Mancuso 1, I Ojima 2, G Scambia 1
PMCID: PMC2363450  PMID: 11104578

Abstract

Taxanes antitumour agents such as paclitaxel and docetaxel represent a successful family of chemotherapeutic drugs. Unfortunately, acquired and innate resistance represents a clinical problem for these drugs. We investigated, on a panel of 7 human cancer cell lines, the growth inhibition effect of 3 newly developed taxanes (SB-T-1213, SB-T-1250 and SB-T-101187) with modification at the C10 and C3′ positions of the taxane framework. These positions have been previously characterized as critical to make taxanes highly active against cells overexpressing the efflux pump P-glycoprotein (P-gp). Paclitaxel and docetaxel were used as reference compounds. Results unambiguously indicate the exceptional activity of the novel taxanes toward P-gp positive cells (up to >400 fold higher potency than that of paclitaxel). SB-T-1213 and SB-T-1250 are also substantially more active than the reference compounds against P-gp negative cells. To better understand the mechanisms underlying the enhanced activity of the newly developed taxanes, we performed cell cycle and apoptosis analysis. This study demonstrates that the striking growth inhibition effect exhibited by the novel taxanes is ascribed to their increased ability in inducing apoptosis and G 2/M cell cycle block. SB-T-1213 and SB-T-1250 are also more active than reference compounds in inducing intracellular accumulation of the beta-tubulin subunits. Finally, it is revealed that these novel taxanes have ability to inhibit the function of the P-gp efflux pump on the basis of the Rhodamine 123 assay. These findings strongly suggest that SB-T-1213, SB-T-1250 and SB-T-101187 represent a new tool to overcome innate or acquired P-gp mediated taxane-resistance. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords: P-glycoprotein, cell cycle block, apoptosis, paclitaxel, taxanes

Full Text

The Full Text of this article is available as a PDF (244.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhalla K., Huang Y., Tang C., Self S., Ray S., Mahoney M. E., Ponnathpur V., Tourkina E., Ibrado A. M., Bullock G. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia. 1994 Mar;8(3):465–475. [PubMed] [Google Scholar]
  2. Chevillard S., Pouillart P., Beldjord C., Asselain B., Beuzeboc P., Magdelénat H., Vielh P. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 1996 Jan 15;77(2):292–300. doi: 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  3. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T., Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 1997 Jan 1;27(1):1–20. [PubMed] [Google Scholar]
  4. De Vincenzo R., Scambia G., Benedetti Panici P., Fattorossi A., Bonanno G., Ferlini C., Isola G., Pernisco S., Mancuso S. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer. 1996 Nov 4;68(3):340–348. doi: 10.1002/(SICI)1097-0215(19961104)68:3<340::AID-IJC12>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  5. Distefano M., Scambia G., Ferlini C., Gaggini C., De Vincenzo R., Riva A., Bombardelli E., Ojima I., Fattorossi A., Panici P. B. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer. 1997 Sep 4;72(5):844–850. doi: 10.1002/(sici)1097-0215(19970904)72:5<844::aid-ijc22>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  6. Ferlini C., Di Cesare S., Rainaldi G., Malorni W., Samoggia P., Biselli R., Fattorossi A. Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry. 1996 Jun 1;24(2):106–115. doi: 10.1002/(SICI)1097-0320(19960601)24:2<106::AID-CYTO2>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  7. Gao Z., Gao Z., Fields J. Z., Boman B. M. Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells. Int J Cancer. 1999 Jul 30;82(3):346–352. doi: 10.1002/(sici)1097-0215(19990730)82:3<346::aid-ijc7>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  8. Herrington J. D., Di Nunno L., Rinehart J. J. Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis. Ann Pharmacother. 1998 May;32(5):611–612. doi: 10.1345/aph.17359. [DOI] [PubMed] [Google Scholar]
  9. Horwitz S. B., Cohen D., Rao S., Ringel I., Shen H. J., Yang C. P. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;(15):55–61. [PubMed] [Google Scholar]
  10. Jordan M. A., Wendell K., Gardiner S., Derry W. B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996 Feb 15;56(4):816–825. [PubMed] [Google Scholar]
  11. Kavallaris M., Kuo D. Y., Burkhart C. A., Regl D. L., Norris M. D., Haber M., Horwitz S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997 Sep 1;100(5):1282–1293. doi: 10.1172/JCI119642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kaye S. B. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol. 1998 Aug;10 (Suppl 1):S15–S19. [PubMed] [Google Scholar]
  13. Long B. H., Fairchild C. R. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res. 1994 Aug 15;54(16):4355–4361. [PubMed] [Google Scholar]
  14. Manfredi J. J., Parness J., Horwitz S. B. Taxol binds to cellular microtubules. J Cell Biol. 1982 Sep;94(3):688–696. doi: 10.1083/jcb.94.3.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mechetner E., Kyshtoobayeva A., Zonis S., Kim H., Stroup R., Garcia R., Parker R. J., Fruehauf J. P. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 1998 Feb;4(2):389–398. [PubMed] [Google Scholar]
  16. Motulsky H. J., Ransnas L. A. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987 Nov;1(5):365–374. [PubMed] [Google Scholar]
  17. Naito M., Tsuruo T. Therapeutic approach to drug resistant tumors. Ther Drug Monit. 1998 Oct;20(5):577–580. doi: 10.1097/00007691-199810000-00022. [DOI] [PubMed] [Google Scholar]
  18. Ojima I., Kuduk S. D., Pera P., Veith J. M., Bernacki R. J. Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity. J Med Chem. 1997 Jan 31;40(3):279–285. doi: 10.1021/jm9606711. [DOI] [PubMed] [Google Scholar]
  19. Ojima I., Slater J. C., Kuduk S. D., Takeuchi C. S., Gimi R. H., Sun C. M., Park Y. H., Pera P., Veith J. M., Bernacki R. J. Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. J Med Chem. 1997 Jan 31;40(3):267–278. doi: 10.1021/jm960563e. [DOI] [PubMed] [Google Scholar]
  20. Ojima I., Slater J. C., Michaud E., Kuduk S. D., Bounaud P. Y., Vrignaud P., Bissery M. C., Veith J. M., Pera P., Bernacki R. J. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem. 1996 Sep 27;39(20):3889–3896. doi: 10.1021/jm9604080. [DOI] [PubMed] [Google Scholar]
  21. Ranganathan S., Benetatos C. A., Colarusso P. J., Dexter D. W., Hudes G. R. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 1998 Feb;77(4):562–566. doi: 10.1038/bjc.1998.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rao S., Horwitz S. B., Ringel I. Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst. 1992 May 20;84(10):785–788. doi: 10.1093/jnci/84.10.785. [DOI] [PubMed] [Google Scholar]
  23. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
  24. Shapiro A. B., Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol. 1997 Feb 21;53(4):587–596. doi: 10.1016/s0006-2952(96)00826-x. [DOI] [PubMed] [Google Scholar]
  25. Smeets M., Raymakers R., Vierwinden G., Pennings A., van de Locht L., Wessels H., Boezeman J., de Witte T. A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol. 1997 Feb;96(2):346–355. doi: 10.1046/j.1365-2141.1997.d01-2024.x. [DOI] [PubMed] [Google Scholar]
  26. Török M., Gutmann H., Fricker G., Drewe J. Sister of P-glycoprotein expression in different tissues. Biochem Pharmacol. 1999 Apr 1;57(7):833–835. doi: 10.1016/s0006-2952(98)00357-8. [DOI] [PubMed] [Google Scholar]
  27. Uchida N., Combs J., Chen S., Zanjani E., Hoffman R., Tsukamoto A. Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities. Blood. 1996 Aug 15;88(4):1297–1305. [PubMed] [Google Scholar]
  28. Verweij J., Clavel M., Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994 Jul;5(6):495–505. doi: 10.1093/oxfordjournals.annonc.a058903. [DOI] [PubMed] [Google Scholar]
  29. Yu D. S., Chang S. Y., Ma C. P. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol. 1998 Oct;82(4):544–547. doi: 10.1046/j.1464-410x.1998.00796.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES